急性前交叉韧带撕裂患者早期抗炎治疗的多中心研究
这项随机对照试验纳入49例急性前交叉韧带撕裂患者,随机分为4组接受不同时间点的关节穿刺抽液和皮质类固醇或生理盐水注射,评估炎症与软骨退变生物标志物的自然进展及疼痛关系。结果显示除MMP-1和TSG-6外,软骨退变标志物在前5周恶化而患者报告结局改善;安慰剂组CTX-II升高显著大于伤后数天内接受皮质类固醇注射的组1和组3。作者认为早期抗炎干预可影响软骨退变生物标志物。
要点
- 急性前交叉韧带撕裂后前5周软骨退变标志物恶化,患者报告结局改善,与治疗分组无关。
- 皮质类固醇注射组与安慰剂组患者报告结局无差异。
- 安慰剂组CTX-II升高显著大于伤后数天内接受皮质类固醇注射的组1和组3。
核心结论
- 创伤后骨关节炎在损伤时即开始,早期即导致膝关节基质显著改变。
- 早期使用抗炎药物能够影响软骨退变的生物标志物。
- 若早期干预能对症状性创伤后骨关节炎的发生或严重程度产生有意义的改变,当前前交叉韧带损伤患者的治疗范式可能需要重构,以纳入早期关节穿刺抽液和关节内干预。
研究设计与样本
- 随机对照试验,证据等级2。
- 共49例患者随机分为4组:组1于前交叉韧带损伤后4天注射皮质类固醇、2周注射生理盐水安慰剂;组2于损伤后4天注射安慰剂、2周注射皮质类固醇;组3于两个时间点均注射皮质类固醇;安慰剂组于两个时间点均注射生理盐水。
- 在损伤后约4天、11天和5周收集患者报告结局指标和滑液生物标志物。
- 使用Wilcoxon检验评估各变量时间点间的变化,通过计算Spearman ρ评估结局评分变化与生物标志物变化的关系,使用Kruskal-Wallis检验比较4组间的结局和生物标志物。
主要发现
- 所有研究患者中未观察到不良事件或感染。
- 除基质金属蛋白酶1(MMP-1)和肿瘤坏死因子诱导基因6(TSG-6)外,软骨退变标志物在前5周恶化,而所有患者报告结局在此期间改善,与治疗分组无关。
- 接受皮质类固醇注射的患者与安慰剂组患者报告结局无差异。
- 与II型胶原 breakdown 相关的II型胶原C端肽(CTX-II)升高在安慰剂组(1.32 ± 1.10 ng/mL)显著大于伤后最初数天内接受皮质类固醇注射的组1(0.23 ± 0.27 ng/mL,P = .01)和组3(0.19 ± 0.34 ng/mL,P = .01)。
关键数值与推荐
- 组1于前交叉韧带损伤后4天注射皮质类固醇、2周注射生理盐水安慰剂。
- 组2于损伤后4天注射安慰剂、2周注射皮质类固醇。
- 组3于损伤后4天和2周两个时间点均注射皮质类固醇。
- 安慰剂组于损伤后4天和2周两个时间点均注射生理盐水。
- CTX-II升高:安慰剂组1.32 ± 1.10 ng/mL vs 组1 0.23 ± 0.27 ng/mL(P = .01)vs 组3 0.19 ± 0.34 ng/mL(P = .01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: It is increasingly recognized that biochemical abnormalities of the joint precede radiographic abnormalities of posttraumatic osteoarthritis (PTOA) by as much as decades. A growing body of evidence strongly suggests that the progression from anterior cruciate ligament (ACL) injury to PTOA is multifactorial, involving the interplay between biomechanical disturbances and biochemical homeostasis of articular cartilage. PURPOSE: The purposes of this randomized study using an acute ACL injury model were to (1) evaluate the natural progression of inflammatory and chondrodegenerative biomarkers, (2) evaluate the relationship between subjective reports of pain and inflammatory and chondrodegenerative biomarkers, and (3) determine if postinjury arthrocentesis and corticosteroid injection offer the ability to alter this biochemical cascade. STUDY DESIGN: Randomized controlled trial; Level of evidence, 2. METHODS: A total of 49 patients were randomized to 4 groups: group 1 (corticosteroid at 4 days after ACL injury, placebo injection of saline at 2 weeks), group 2 (placebo at 4 days after ACL injury, corticosteroid at 2 weeks), group 3 (corticosteroid at both time intervals), or a placebo group (saline injections at both time intervals). Patient-reported outcome measures and synovial biomarkers were collected at approximately 4 days, 11 days, and 5 weeks after injury. The change between the time points was assessed for all variables using Wilcoxon tests, and the relationship between changes in outcome scores and biomarkers were assessed by calculating Spearman ρ. Outcomes and biomarkers were also compared between the 4 groups using Kruskal-Wallis tests. RESULTS: No adverse events or infections were observed in any study patients. With the exception of matrix metalloproteinase 1 (MMP-1) and tumor necrosis factor-inducible gene 6 (TSG-6), chondrodegenerative markers worsened over the first 5 weeks while all patient-reported outcomes improved during this time, regardless of treatment group. Patient-reported outcomes did not differ between patients receiving corticosteroid injections and the placebo group. However, increases in C-telopeptide of type II collagen (CTX-II), associated with collagen type II breakdown, were significantly greater in the placebo group (1.32 ± 1.10 ng/mL) than in either of the groups that received the corticosteroid injection within the first several days after injury (group 1: 0.23 ± 0.27 ng/mL [ P = .01]; group 3: 0.19 ± 0.34 ng/mL [ P = .01]). CONCLUSION: PTOA begins at the time of injury and results early on in dramatic matrix changes in the knee. However, it is encouraging that early intervention with an anti-inflammatory agent was able to affect biomarkers of chondral degeneration. Should early intervention lead to meaningful changes in either the onset or severity of symptomatic PTOA, the current treatment paradigm for patients with ACL injury may have to be restructured to include early aspiration and intra-articular intervention. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01692756.
引用
- Lattermann C, Jacobs CA, Proffitt Bunnell M, et al. A Multicenter Study of Early Anti-inflammatory Treatment in Patients With Acute Anterior Cruciate Ligament Tear. Am J Sports Med. 2016. PMID: 28146402. doi:10.1177/0363546516666818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。